Mylan faces a tough battle to consummate its hostile bid for Perrigo Co. even if it wins a crucial shareholder vote later this month, Perrigo chairman, president and CEO Joseph Papa told analysts Wednesday.
Mr. Papa also reiterated his belief that Mylan’s unsolicited bid for the Irish over-the-counter drugmaker is too low and is not in the best interest of its shareholders.
“Mylan’s offer substantially undervalues our business,” Mr. Papa told analysts during a conference call discussing Perrigo’s second-quarter results.
Mylan shareholders are scheduled to vote Aug. 28 at a special shareholder meeting in Amsterdam on whether to submit a tender offer to Perrigo shareholders based on a proposal Mylan made in April. That offer of $75 in cash and 2.3 Mylan shares for each Perrigo share was rebuffed unanimously by Perrigo’s board.
Mylan is based in the Netherlands but maintains its base of operations in Cecil.
Mr. Papa told analysts that should Mylan shareholders approve making a tender offer for Perrigo shares, the company has strategic options. He said the Dublin-based company is generating enough cash to finance acquisitions of its own.
Read More
“We are focused on running our standalone business,” he told analysts.
Jeffrey Loo, S&P Capital IQ analyst, said he believes Mylan shareholders will vote against submitting an offer to Perrigo. Based on that assumption, he lowered his 12-month price target on Perrigo stock from $222 to $200.
Mr. Papa was vague when asked about differences between the corporate culture of Perrigo and Mylan, saying only that “there’s no doubt that there are differences in the management styles of the two companies.”
Analysts had seen Mylan’s hostile bid for Perrigo as a defensive measure to thwart Teva Pharmaceutical Industries’ unsolicited $82-per-share offer for Mylan. Teva dropped that bid last month when it agreed to acquire the generics business of Allergan PLC for $40.5 billion.
Since then, Mylan shares have plummeted 17 percent, reducing the value of the company’s offer for Perrigo. Based on Mylan’s current share price, the offer values Perrigo at about $201 per share.
Shares of Mylan, which reports second-quarter results today, finished Wednesday at $54.60, down 7 cents. Perrigo closed at $189.65, down 99 cents.
Len Boselovic: lboselovic@post-gazette.com or 412-263-1941.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.